The A1Cs of diabetes monitoring.
Given the advancements in diabetes treatment today, it’s easy to forget how far we’ve come from the days when scientists first began to gain a better understanding of diabetes and how patients could minimize long- term complications from this disease.
Since the 1950s, diabetics have managed their disease by monitoring the sugar (glucose) level of their blood to determine the level of insulin their body required at a given time. However, for the many diabetics who manage their disease with
a combination of diet, exercise, and medication, monitoring their glucose levels on a regular basis is not the only way of letting them know how effective their therapy is over a longer period of time.
In the 1970s, it was discovered that “glycosylated” hemoglobin (GHb), which contained a protein called hemoglobin A1, showed elevated levels in diabetics. GHb offered insight into average blood glucose levels in diabetics over a several-month period, and therefore provided a more representative baseline for monitoring and controlling their disease. This exciting development was tempered by the fact that testing hemoglobin A1 was a cumbersome and expensive process.
Upon the discovery of hemoglobin A1, Bio-Rad researchers began to think of ways to provide more efficient separation that would be suitable for routine use in the clinical laboratory. By 1978, the Bio-Rad team developed the first commercial test for monitoring hemoglobin A1 in diabetics using a small, disposable, and inexpensive open chromatography column.
Further efficiencies were still to come. The separated hemoglobin A1 still contained impurities that affected the measurement, causing some uncertainty in the results. By 1982, in the process of eliminating these interferences caused by impurities associated with the existing test, Bio-Rad became the first company to measure A1C, a subset of hemoglobin A1 and a more precise indicator of average blood glucose levels over time. As the new test became established as a useful clinical tool, test volumes increased rapidly, and Bio-Rad introduced a series of automated high-performance liquid chromatography (HPLC) platforms to further improve performance and laboratory efficiency.
Today, Bio-Rad advancements continue to lead the way in monitoring treatment regimens for the more than 14 million Americans who have been diagnosed with diabetes and who are part of the approximately 200 million worldwide who suffer from the disease.
|